Enfortumab Vedotin Shows Varied Efficacy Across Primary and Metastatic Urothelial Carcinoma Sites
A recent study evaluating enfortumab vedotin (EV) in metastatic urothelial carcinoma (UC) shows varied tumor shrinkage rates between primary and metastatic sites.
© Copyright 2025. All Rights Reserved by MedPath